OCT 14·SEC EDGARLow
FRANCIS LAURA sold $762K of SIBN (indirect holdings)
FRANCIS LAURA (Chief Executive Officer) sold 38,006 indirectly-held shares of SI-BONE, Inc. (SIBN) at $20.05 ($0.76M total) on 2026-10-12 under a Rule 10b5-1 trading plan.
StockNASDAQ · US · USDHealthcare · Medical Devices
$SIBN
SI-BONE, Inc.
Price · $SIBNvia TradingView
AI sentiment · 7d0 articles
No enriched coverage for $SIBN in the last 7 days.
Insider · 30dAll trades →
- Buys
- — 0 txs
- Sells
- $1.3M 8 txs
PISETSKY MICHAEL A.3× · $57K
10b5-1 share of filings62%
Top stories · $SIBNMore →
OCT 2·rttnews.com
Weekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data
Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.
SEP 28·investing.com
SI-Bone stock gains after FDA clears spinal fusion system
SI-Bone Inc (SIBN) shares rose 2.8% after receiving FDA 510(k) clearance for its iFuse Granite Onyx System, its first product for spinal fusion outside the pelvis. The system aims to address screw loosening in spinal fusions. CEO Laura Francis noted it is the company's third breakthrough device designation.
SIBN sentiment & insider activity
Recent SIBN coverage spans insider activity, regulation and corporate actions.
In the last 30 days, SIBN insiders filed 8 SEC Form 4 transactions — no purchases and 8 sales ($1.3M). The most active reporter was PISETSKY MICHAEL A., SVP, Ops & Adm/Chief Legal Ofr, with 3 filings. 62% of those filings were made under pre-arranged Rule 10b5-1 plans.
What's driving SIBN
The insider sale may signal confidence concerns and could exert slight downward pressure on the stock.
Clearance may increase adoption and revenue, likely supporting the share price.
Positive regulatory approval expected to lift the stock.
Recall may modestly pressure the stock; lease extension is minor. Potential short‑term downside if costs exceed expectations.
The insider sale may signal confidence concerns, potentially exerting slight downward pressure on SIBN.
AlphAI scores every news story that mentions SIBN with an AI model for sentiment and relevance, and aggregates insider trades from SI-BONE, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $SIBN
Score
FRANCIS LAURA sold $762K of SIBN (indirect holdings)
FRANCIS LAURA (Chief Executive Officer) sold 38,006 indirectly-held shares of SI-BONE, Inc. (SIBN) at $20.05 ($0.76M total) on 2026-10-12 under a Rule 10b5-1 trading plan.
1 min readWeekly Buzz: EW, ABBV, MIRM Score FDA Wins, AZN, NVO Strike Deals; LLY, KOD Report Data
Edwards Lifesciences (EW) received FDA approval for a pediatric heart valve. Ceribell (CBLL) and SI-BONE (SIBN) cleared new software and spinal fusion systems. Teva (TEVA) added a biosimilar to its portfolio. AbbVie (ABBV) and Mirum (MIRM) gained FDA approvals for Parkinson's and rare disease treatments. Merck (MRK) withdrew a lung cancer drug filing. Sanofi (SNY) and Regeneron (REGN) expanded their immunology alliance.
3 min readSI-Bone stock gains after FDA clears spinal fusion system
SI-Bone Inc (SIBN) shares rose 2.8% after receiving FDA 510(k) clearance for its iFuse Granite Onyx System, its first product for spinal fusion outside the pelvis. The system aims to address screw loosening in spinal fusions. CEO Laura Francis noted it is the company's third breakthrough device designation.
2 min readSI-BONE, Inc. (SIBN): Entry into a Material Definitive Agreement
SI-BONE, Inc. (SIBN) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. On September 11, 2026, SI-BONE, Inc. (the “Company”) and BIXBY SPE FINANCE 11, LLC (“Landlord”) entered into the Fourth Amendment to Lease (the “Fourth Lease Amendment”) to the Office Lease Agreement dated as of February 2, 2
1 min readFRANCIS LAURA sold $523K of SIBN (indirect holdings)
FRANCIS LAURA (Chief Executive Officer) sold 25,972 indirectly-held shares of SI-BONE, Inc. (SIBN) at $20.12 ($0.52M total) on 2026-08-24 under a Rule 10b5-1 trading plan.
1 min readSI-BONE (NASDAQ: SIBN) trust to sell 25,972 shares under Rule 144
SI-BONE (SIBN) reported that a trust plans to sell 25,972 shares of its common stock under Rule 144. The shares were acquired from restricted stock units that vested starting May 15, 2021. The filing also details recent sales by the trust and Laura Francis, including 10b5-1 plan transactions.
1 min readFRANCIS LAURA sold $1.1M of SIBN (indirect holdings)
FRANCIS LAURA (Chief Executive Officer) sold 55,807 indirectly-held shares of SI-BONE, Inc. (SIBN) at an average of $19.50 ($19.46–$20.02, $1.09M total) across 2 trades over 2026-08-20 to 2026-08-21 under a Rule 10b5-1 trading plan.
1 min readFRANCIS LAURA sold $279K of SIBN
FRANCIS LAURA (Chief Executive Officer) sold 14,956 shares of SI-BONE, Inc. (SIBN) at an average of $18.66 ($18.63–$18.68, $0.28M total) across 5 trades on 2026-08-17.
2 min readSI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance
SI-BONE, Inc. (SIBN) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 SI-BONE, Inc. Reports Financial Results for the Second Quarter 2026 and Raises 2026 Guidance Delivered ~15% WW revenue growth and ~178% increase in adjusted EBITDA ~19% increase in U.S. physician base Second Quarter 2026 Financial Highlights (all comparisons are to t
6 min read
SIBN Q2'26 Earnings: EPS estimate is (0.15) USD
Si-Bone, Inc. (SIBN) is scheduled to report Q2 2026 earnings on Aug. 3 after market close, with results expected at 4:09 PM ET. The consensus outlook cited for the quarter includes revenue of $55.34 million and EPS of -$0.15 (USD).
1 min read